![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Tesla
TSLA
Netflix
NFLX
Adobe
ADBE
Alphabet-A
GOOGL
Alphabet-C
GOOG
US Stock MarketDetailed Quotes
THAR Tharimmune
- 1.460
- -0.070-4.58%
Close Mar 25 16:00 ET
- 1.690
- +0.230+15.75%
Post 19:59 ET
2.82MMarket Cap0.02P/E (TTM)
1.620High1.400Low42.70KVolume1.470Open1.530Pre Close64.45KTurnover2.24%Turnover RatioLossP/E (Static)1.93MShares7.46152wk High0.94P/B2.78MFloat Cap1.28052wk Low--Dividend TTM1.90MShs Float1590.000Historical High--Div YieldTTM14.38%Amplitude1.280Historical Low1.509Avg Price1Lot Size
Tharimmune Stock Forum
Sign in to post a comment
NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If y...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If y...
31
7
1
$Tharimmune (THAR.US)$
Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha
Monday, 24th March at 8:00 am
BRIDGEWATER, NJ / ACCESS Newswire / March 24, 2025 / Tharimmune, Inc. (NASDAQ: THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation, today announced positive preclinical results for its novel oral antibody, TH023. In a murine model, a proprietary protease enzyme...
Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha
Monday, 24th March at 8:00 am
BRIDGEWATER, NJ / ACCESS Newswire / March 24, 2025 / Tharimmune, Inc. (NASDAQ: THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation, today announced positive preclinical results for its novel oral antibody, TH023. In a murine model, a proprietary protease enzyme...
2
$Tharimmune (THAR.US)$
Can Tharimmune's Dual-Target Cancer Drugs Outperform Traditional Antibody Therapies?
Can Tharimmune's Dual-Target Cancer Drugs Outperform Traditional Antibody Therapies?
$Tharimmune (THAR.US)$
Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology
Tuesday, 4th March at 7:00 am
BRIDGEWATER, NJ / ACCESS Newswire / March 4, 2025 / Tharimmune, Inc. (NASDAQ: THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation, today announced the expansion of its product pipeline with HS1940, a dual-target mult...
Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology
Tuesday, 4th March at 7:00 am
BRIDGEWATER, NJ / ACCESS Newswire / March 4, 2025 / Tharimmune, Inc. (NASDAQ: THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation, today announced the expansion of its product pipeline with HS1940, a dual-target mult...
1
$Tharimmune (THAR.US)$ Reuters· just
Tharimmune: Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis
Tharimmune: Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis
$Tharimmune (THAR.US)$
Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update
Monday, 16th December at 8:00 am
BRIDGEWATER, NJ / ACCESSWIRE / December 16, 2024 / Tharimmune, Inc. (NASDAQ: THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced plans for initiating a Phase 2 st...
Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update
Monday, 16th December at 8:00 am
BRIDGEWATER, NJ / ACCESSWIRE / December 16, 2024 / Tharimmune, Inc. (NASDAQ: THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced plans for initiating a Phase 2 st...
$Tharimmune (THAR.US)$ This is interesting, good volumes observed on post market. Keep an eye on this.
1
No comment yet
Market Insights
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Yubraj : @Jaguar8 brother how about TNON
Yubraj Yubraj : is it in your radar or not?
Jaguar8 OP Yubraj : Yes it is but it will be on stocks with news which i will post later. Still reviewing others stocks with news. It will be included for sure
Yubraj Jaguar8 OP : thank you
72149607 : what u think about VVPR jag bro pre market today?
View more comments...